Évaluation économique du dépistage et du traitement de l’hépatite C

Hepatitis C Antibodies among Blood Donors, Senegal, 2001

“…This screening cost could be reduced by discarding blood units that test positive after only one enzyme-linked immunosorbent assay (156,000 CFA or U.S.$237), at the price of nearly 3% of blood units wrongly discarded. France has demonstrated that this strategy has the best cost-effectiveness ratio, as long as the prevalence remains below 8% ( 9 ). This cost compares favorably with the cost per HIV infection averted through improvement of blood safety (range U.S.$20–U.S.$1,000), assessed in some highly HIV-prevalent southern African countries (Tanzania, Zambia, Zimbabwe) ( 10 ).…”